John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Do we have to take into account insulin resistance in chronic hepatitis C ? Volume 17, supplement 5, novembre 2010

Figures

See all figures

Author
Service d'hépatologie, Hôpital Saint Antoine, Inserm UMR S893, Université Pierre et Marie Curie, Paris 75571, France

Insulin resistance is frequent in chronic hepatitis C and promoted by classical metabolic factors but also by factors associated with HCV infection it self, defining viral insulin resistance. Consequences of insulin resistance are progression of disease and response to antiviral treatment. In the majority of studies, insulin resistance is measured by using HOMA index which has a negative impact on response to treatment when higher than 2, whatever the genotype and independently from other predictive factors. Insulinsensitzing molecules as adjuvant treatment to combination therapy warrent further confirmation prior to be routinely used in insulin resistant patients.